Tag: cell therapy

5
Jul 2017

Bionest

FDA: Thinking “Outside the Box”

On May 17, the U.S. Food and Drug Administration granted an expanded approval to Vertex’s Kalydeco (ivacaflor), tripling the number of mutations in the cystic fibrosis (CF)-associated gene CFTR that the drug can treat, from 10 to 33. The agency’s action was unusual in that, for the first time ever, they based their decision on...
3
Apr 2017

Bionest

National Academies of Science and Medicine Cautiously Endorse Some Germline Gene Editing — In the Future

  In February the National Academy of Sciences and the National Academy of Medicine issued a new report on the technical, social and regulatory concerns surrounding gene editing, entitled, “Human Genome Editing: Science, Ethics, and Governance.” Authored by a 22 member panel of scientists, ethicists, lawyers, physicians and geneticists from around the world, the report...
15
Dec 2015

Bionest

Visit Us at the JP Morgan Healthcare Conference – Jan 11-14 in San Francisco!

We are looking forward to attending the JP Morgan Healthcare Conference again January 11-14, 2016, in San Francisco.   Three of Bionest’s leaders, Alain J. Gilbert, Olivier Lesueur, and Bob Easton, will be available to meet one-on-one for 30 minutes in our private suite, between Monday Jan 11 and Thursday Jan 14.   For Bionest,...
9
Dec 2015

Bionest

BIO Europe 2015 Conference – Reflections

Bionest attended BIO Europe in Munich last month and witnessed firsthand the flurry of deal making activity.  In many ways 2015 has been a landmark year for deal making.  Companies big and small have made headlines, striking deals across every corner of the industry and for myriad reasons ranging from combination collaborations to the recent...